Beckwith‑Wiedemann Syndrome: Evidence‑Based Tumor Surveillance and Management Guidelines

Tumor Surveillance Protocol

All children with Beckwith‑Wiedemann syndrome should undergo renal ultrasonography (including adrenal glands) every 3 months from birth until the 7th birthday to screen for Wilms tumor, and a full abdominal ultrasound with serum alpha‑fetoprotein (AFP) measurement every 3 months from birth through the 4th birthday to screen for hepatoblastoma. 1, 2

A 3‑month ultrasound interval is critical; extending the interval beyond 4 months markedly increases the risk of interval tumor development. 2
Approximately 93 % of Wilms tumors in this population arise before age 8 years, with a mean age at diagnosis of about 24 months. 2
The surveillance frequency does not change with patient age because tumor growth rates are age‑independent. 2

Serum AFP testing combined with abdominal ultrasound every 3 months from birth through the 4th birthday provides highly sensitive detection of hepatoblastoma. 2
The majority of hepatoblastomas present within the first year of life; the oldest reported case occurred at 30 months. 2
After the 4th birthday, surveillance shifts to renal‑only ultrasound every 3 months until the 7th birthday. 2

North American clinical practice guidelines recommend uniform tumor surveillance for all Beckwith‑Wiedemann patients regardless of molecular subtype. 1, 2
This uniform approach contrasts with some European centers that apply subtype‑specific screening protocols. 1, 2

Patients should be followed by cancer‑predisposition specialists (geneticists or pediatric oncologists) who conduct comprehensive monitoring. 1, 2
Specialist physical examinations are advised twice yearly to reinforce education, assess compliance, and evaluate other syndrome‑related features. 2

Wilms‑tumor surveillance must continue through age 7, not stop at age 4, because 93 % of tumors occur before age 8. 2
Relying solely on clinical features is insufficient; molecular testing is essential, as 16 % of children with Wilms tumor have at least one Beckwith‑Wiedemann feature without classic presentation. 3
Beckwith‑Wiedemann syndrome confers an approximately 2,280‑fold increased relative risk for hepatoblastoma compared with the general pediatric population. 2

Patients with Beckwith-Wiedemann Syndrome require standardized tumor surveillance with renal ultrasounds every 3 months from birth through age 7 for Wilms tumor detection and abdominal ultrasound with alpha-fetoprotein measurements every 3 months through age 4 for hepatoblastoma screening, regardless of molecular subtype 4, 5
Beckwith-Wiedemann Syndrome is a rare overgrowth syndrome characterized by pre- and postnatal constitutional and organ overgrowth 4
The incidence is approximately 1 in 10,500 births, though likely higher when including subtle cases with isolated hemihyperplasia 4

BWS is caused by dysregulation of imprinted growth genes on chromosome 11p15, with several molecular subtypes, including gain of methylation at imprinting control region 1 (IC1/H19/IGF2:IG-DMR) 4
Genetic counseling is recommended due to the complexity of inheritance patterns 4

Overall tumor risk is 5-10%, but varies significantly by molecular subtype, with IC1 gain of methylation having a 28% risk (primarily Wilms tumor) 4
Standardized tumor surveillance recommendations include Wilms tumor screening with renal ultrasounds every 3 months from birth through the 7th birthday 5, 6
Hepatoblastoma screening should include full abdominal ultrasound and alpha-fetoprotein (AFP) measurements every 3 months from birth through the 4th birthday 5, 6
Neuroblastoma screening is recommended for patients with CDKN1C mutations, with urine catecholamines and chest radiographs 4, 7

Abdominal wall defects require surgical repair of omphalocele or umbilical hernia 4

Tumor screening should be performed by specialists familiar with cancer predisposition syndromes 5
Patients with BWS should be evaluated by a multidisciplinary team including geneticists, oncologists, and other specialists as needed 5